Trial Profile

A Master Protocol for the Multi-Cohort, Phase 1/2 Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 13 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cetuximab (Primary) ; DCC 3116 (Primary) ; Encorafenib (Primary) ; Ripretinib (Primary)
Indications Colorectal cancer; Gastrointestinal stromal tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Deciphera Pharmaceuticals

Most Recent Events

14 Nov 2024 Planned End Date changed from 1 Jun 2027 to 1 Mar 2029.
04 Jun 2024 Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology
03 Jun 2024 According to Deciphera Pharmaceuticals media release, trial in progress poster from this trial will be presented at the 2024 ASCO Annual Meeting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com